Infliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated

Inflamm Bowel Dis. 2021 Nov 15;27(12):2031-2033. doi: 10.1093/ibd/izab131.

Authors

Jessica R Allegretti^{1

2}, Andrew Canakis³, Emma McClure¹, Jenna Marcus¹, Beth-Ann Norton¹, Matthew J Hamilton^{1

2}, Rachel W Winter^{1

2}, Punyanganie S De Silva^{1

2}, Sonia Friedman^{1

2}, Joshua R Korzenik^{1

2}

Affiliations

¹ Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
² Harvard Medical School, Boston, Massachusetts, USA.
³ Department of Medicine, Boston University Medical Center, Boston, Massachusetts, USA.

PMID: 34142700
DOI: 10.1093/ibd/izab131

No abstract available

Keywords: Crohn’s disease; dose de-escalation; inflammatory bowel disease; infliximab.

MeSH terms

Antibodies, Monoclonal
Crohn Disease* / drug therapy
Gastrointestinal Agents / administration & dosage*
Humans
Infliximab / administration & dosage*
Remission Induction
Treatment Outcome

Substances

Antibodies, Monoclonal
Gastrointestinal Agents
Infliximab